Genentech, Inc.

Oncology sponsors will face increased US Food and Drug Administration scrutiny about patient enrollment and site selection for multiregional trials, as well as the relevance of comparator arms to US s

Roche affiliate Genentech revealed on July 18 that the US Food and Drug Administration denied a supplemental approval for its bispecific antibody Columvi (glofitamab-gxbm) in relapsed/refractory diffu

BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q2 2025. While the flow of money was mostly anemic, a couple of standouts are a $2

The US Centers for Medicare and Medicaid Services’ proposal to select certain fixed-dose drug combinations for Medicare price negotiation is “impermissibly” at odds with the US Food and Drug Administr